 AC Immune SA ACIU, a Swiss-based, clinical-stage biopharmaceutical company, today announced that it will receive a second milestone payment of CHF 10 million from Eli Lilly and Company on or before March 31, 2020 related to development progress in the small molecule MorphomerTM Tau aggregation inhibitor program. The multi-year collaboration agreement between Lilly and AC Immune was originally announced in December 2018 and focuses on the broad development of MorphomerTM Tau aggregation inhibitors for Alzheimers disease AD and other neurodegenerative diseases. 